Abstract: Objective  To evaluate the efficacy of carvedilol in treatment of dilated cardiomyopathy.Methods  The PubMed， the Cochrane Central Register of Controlled Trials（CENTRAL）， Clinical Trials.gov (https://clinicaltrials.gov/)， WanFang Data， CNKI， CBM and VIP database were  retrieved to collect randomized controlled trials of carvedilol in the treatment of dilated cardiomyopathy before October 2016. RevMan5.3 software was used to analyze  the data. Results  A total of 810 patients (9 randomized controlled trials) were included. In the metaanalysis， the left ventricular ejection fraction (MD=8.03，95%CI=6.479.58，P<0.01)  was significantly higher in the carvedilol group compared to placebo group， the heart rate (MD=-9.21，95%CI=-11.81-2.40，P<0.003)， left ventricular end diastolic diameter (MD=-7.11， 95%CI=-11.81-2.40，P<0.003) and mortality (OR=0.33， 95%CI=-18.612.85，P=0.15)  were significantly lower in the carvedilol group compared to placebo group， systolic blood pressure (MD=-7.88，95%CI=-18.612.85，P=0.15，  and diastolic blood pressure (MD=-1.15，95%CI=-5.483.17，P=0.60)  were similar between the carvedilol group and placebo group. Conclusion  In patients with dilated cardiomyopathy， carvedilol can improve left ventricular ejection fraction， decrease left ventricular end diastolic diameter and improve heart function furthermore. Meanwhile carvedilol can slow down heart rate and reduce mortality， while blood pressure was not significantly affected.However， its impact on mortality still needs further study.

Key words: cardiomyopathy, dilated；carvedilol, meta analysis